Arlo director executes 10b5-1 sale of 60,787 shares at $16.61
Rhea-AI Filing Summary
Prashant Aggarwal, a director of Arlo Technologies, Inc. (ARLO), reported a sale of 60,787 shares of Arlo common stock on 08/14/2025 under a Rule 10b5-1 trading plan adopted May 15, 2025. The weighted average sale price was $16.6127 with individual trade prices ranging from $16.41 to $17.07. After the sales, the reporting person beneficially owned 10,520 shares. The Form 4 was signed by an attorney-in-fact on 08/15/2025.
Positive
- Sale executed under a Rule 10b5-1 plan, indicating pre-authorization and reduced likelihood of opportunistic trading
- Clear disclosure of weighted average price ($16.6127) and price range ($16.41–$17.07), providing execution transparency
- Form 4 filed and signed promptly (attorney-in-fact signature dated 08/15/2025), meeting disclosure requirements
Negative
- Large reduction in beneficial holdings: 60,787 shares sold, leaving only 10,520 shares beneficially owned, which materially lowers the reporting person’s stake
- Potential perception issue: Significant insider sale may be interpreted unfavorably by some investors despite 10b5-1 plan status
Insights
TL;DR: Director executed a pre-planned sale of most holdings, yielding proceeds at a $16.61 average price; residual stake is modest.
The sale of 60,787 shares under a Rule 10b5-1 plan indicates the transactions were pre-authorized and not opportunistic trades following material nonpublic information disclosed after the plan date. The weighted average price of $16.6127 and the reported price range provide transparency on execution. The residual beneficial ownership of 10,520 shares is a small remaining position, which may modestly reduce insider alignment with shareholders but is a routine disclosure rather than a company performance signal.
TL;DR: Filing documents a compliant, pre-arranged insider sale; disclosure and signature by attorney-in-fact follow Form 4 standards.
The Form 4 clearly flags the use of a 10b5-1 plan adopted May 15, 2025, satisfying affirmative defense disclosure. The submission includes price range and average price and notes willingness to provide full price-by-price details if requested. The filing appears procedurally complete and timely, with an attorney-in-fact signature dated 08/15/2025.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 60,787 | $16.6127 | $1.01M |
Footnotes (2)
- F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2025.
- F2. The weighted average sale price for the transaction reported was $16.6127, and the range of prices were between $16.41 and $17.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
AI-generated analysis. How Rhea-AI works. Not financial advice.